<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34379621</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Prognosis of amyotrophic lateral sclerosis with cognitive and behavioural changes based on a sixty-month longitudinal follow-up.</ArticleTitle><Pagination><StartPage>e0253279</StartPage><MedlinePgn>e0253279</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0253279</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0253279</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Approximately 50% of amyotrophic lateral sclerosis (ALS) patients have cognitive and behavioural dysfunction in varying degrees and forms. Previous studies have shown that cognitive and behavioural changes may indicate a poor prognosis, and cognitive function gradually deteriorates over the course of disease, but the results of different studies have been inconsistent. In addition, there are relatively limited long-term follow-up studies tracking death as an endpoint. The purpose of this study was to investigate the clinical prognostic characteristics of ALS patients with cognitive behavioural changes through long-term follow-up in a cohort.</AbstractText><AbstractText Label="METHODS">A total of 87 ALS patients from 2014 to 2015 in the Third Hospital of Peking University were selected and divided into a pure ALS group, an ALS with behavioural variant of frontotemporal dementia (ALS-bvFTD) group, and an ALS with cognitive and behaviour changes group. All patients were followed up for 60 months. The main end point was death and tracheotomy.</AbstractText><AbstractText Label="RESULTS">There was no significant difference in survival curve between pure ALS and ALS with cognitive and behavioural change group, but the survival time of ALS-bvFTD group was significantly lower than the other two groups (P &lt; 0.001). For those who was followed up to the endpoint, the survival time of the ALS-bvFTD group was significantly shorter than that of the pure ALS group (t = 5.33, p &lt; 0.001) or the ALS with cognitive and behaviour changes group (t = 4.25, p &lt; 0.001). The progression rate of ALS Functional Rating Scale-Revised (FRS-R) scores from recruitment to endpoint was significantly faster in the ALS-bvFTD group than in the pure ALS group (z = 2.68, p = 0.01) or the ALS with cognitive and behavioural changes group (z = 2.75, p = 0.01). There was no significant difference in survival time (t = 0.52, P = 0.60) or FRS-R score progression rate (z = 0.31, p = 0.76) between the pure ALS group and the ALS with cognitive and behavioural changes group. The total Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS) score was positively correlated with survival time (r = 0.38, p = 0.01).</AbstractText><AbstractText Label="CONCLUSION">ALS-bvFTD patients have shorter survival time. The total ECAS score may be correlated with survival time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurology Department, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Pingping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neurology Department, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neurology Department, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neurology Department, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Dongsheng</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-6679-0864</Identifier><AffiliationInfo><Affiliation>Neurology Department, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000066553" MajorTopicYN="N">Problem Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>11</Day><Hour>17</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34379621</ArticleId><ArticleId IdType="pmc">PMC8357115</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0253279</ArticleId><ArticleId IdType="pii">PONE-D-20-39850</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Burrell JR, Halliday GM, Kril JJ, et al.. The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016; 388(10047):919&#x2013;931. doi: 10.1016/S0140-6736(16)00737-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00737-6</ArticleId><ArticleId IdType="pubmed">26987909</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al.. Amyotrophic lateral sclerosis&#x2014;frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 18(3&#x2013;4):153&#x2013;174. doi: 10.1080/21678421.2016.1267768</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Iazzolino B, Pain D, Peotta L, et al.. Validation of the revised classification of cognitive and behavioural impairment in ALS. J Neurol Neurosurg Psychiatry. 2019; 90(7):734&#x2013;739. doi: 10.1136/jnnp-2018-319696</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319696</ArticleId><ArticleId IdType="pubmed">30733331</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol. 2013;12:368&#x2013;80 doi: 10.1016/S1474-4422(13)70026-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70026-7</ArticleId><ArticleId IdType="pubmed">23518330</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J, Elamin M, Bede P, Jordan N, Gallagher L, Byrne S, et al.. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2012;83:102&#x2013;8. doi: 10.1136/jnnp-2011-300188</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-300188</ArticleId><ArticleId IdType="pubmed">21836033</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M., Phukan J., Bede P., et al.. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology. 2011;76(14):1263&#x2013;1269. doi: 10.1212/WNL.0b013e318214359f</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318214359f</ArticleId><ArticleId IdType="pubmed">21464431</ArticleId></ArticleIdList></Reference><Reference><Citation>Caga J., Turner M. R., Hsieh S., et al.. Apathy is associated with poor prognosis in amyotrophic lateral sclerosis. European Journal of Neurology. 2016;23(5):891&#x2013;897. doi: 10.1111/ene.12959</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12959</ArticleId><ArticleId IdType="pubmed">26822417</ArticleId></ArticleIdList></Reference><Reference><Citation>Bersano E, Sarnelli MF, Solara V, Iazzolino B, Peotta L, De Marchi F, et al.. Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study. Amyotroph Lateral Scler Frontotemporal Degener. 2020Aug;21(5&#x2013;6):373&#x2013;379. doi: 10.1080/21678421.2020.1771732</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1771732</ArticleId><ArticleId IdType="pubmed">32484726</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley S, Goetz R, Factor-Litvak P, Murphy J, Hupf J, Garofalo DC, et al.. Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients. Behav Neurol. 2018Oct31;2018:5969137. doi: 10.1155/2018/5969137</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/5969137</ArticleId><ArticleId IdType="pmc">PMC6234441</ArticleId><ArticleId IdType="pubmed">30515252</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Moglia C, Canosa A, Manera U, Vasta R, Brunetti M, et al.. Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology. 2019Sep3;93(10):e984&#x2013;e994. doi: 10.1212/WNL.0000000000008063</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008063</ArticleId><ArticleId IdType="pmc">PMC6745732</ArticleId><ArticleId IdType="pubmed">31409738</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, et al.. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. 2018Oct9;91(15):e1370&#x2013;e1380. doi: 10.1212/WNL.0000000000006317</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006317</ArticleId><ArticleId IdType="pmc">PMC6177274</ArticleId><ArticleId IdType="pubmed">30209236</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter MK, Traynor BJ, Farren J, Braun LE, Tierney M, Wiggs EA, et al.. Disease progression in C9orf72 mutation carriers. Neurology. 2017; 89(3):234&#x2013;241. doi: 10.1212/WNL.0000000000004115</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004115</ArticleId><ArticleId IdType="pmc">PMC5513817</ArticleId><ArticleId IdType="pubmed">28615433</ArticleId></ArticleIdList></Reference><Reference><Citation>Mioshi E., Caga J., Lillo P., et al.. Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. Neurology. 2014;82(2):149&#x2013;155. doi: 10.1212/WNL.0000000000000023</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000023</ArticleId><ArticleId IdType="pubmed">24336140</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhardt C, Neuwirth C, Weber M. Longitudinal assessment of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): lack of practice effect in ALS patients? Amyotroph Lateral Scler Frontotemporal Degener. 2017May;18(3&#x2013;4):202&#x2013;209. doi: 10.1080/21678421.2017.1283418</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1283418</ArticleId><ArticleId IdType="pubmed">28165766</ArticleId></ArticleIdList></Reference><Reference><Citation>Brook BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000, 1(5), 293&#x2013;299. doi: 10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye S, Ji Y, Li CY, He J, Liu X, Fan DS. The Edinburgh Cognitive and Behavioural ALS Screen in a Chinese Amyotrophic Lateral Sclerosis Population. PLoS One. 2016;11(5):e0155496.doi: 10.1371/journal.pone.0155496</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0155496</ArticleId><ArticleId IdType="pmc">PMC4873026</ArticleId><ArticleId IdType="pubmed">27195772</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al.. Sensitivity of revisedvdiagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456&#x2013;77. doi: 10.1093/brain/awr179</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Govaarts R, Beeldman E, Kampelmacher MJ, Tol MV, van den Berg LH, van der Kooi AJ et al.. The frontotemporal syndrome of ALS is associated with poor survival. J Neurol. 2016;263(12):2476&#x2013;2483. doi: 10.1007/s00415-016-8290-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8290-1</ArticleId><ArticleId IdType="pmc">PMC5110703</ArticleId><ArticleId IdType="pubmed">27671483</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Ilardi A, Cammarosano S, Moglia C, Montuschi A, Calvo A. Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV. Neurology. 2012;78:1085&#x2013;1089. doi: 10.1212/WNL.0b013e31824e8f53</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31824e8f53</ArticleId><ArticleId IdType="pubmed">22442427</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrilees J, Klapper J, Murphy J, Lomen-Hoerth C, Miller BL. Cognitive and behavioral challenges in caring for patients with frontotemporal dementia and amyotrophic lateral sclerosis. Amyotroph Later Scler. 2010;11:298&#x2013;302. doi: 10.3109/17482961003605788</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482961003605788</ArticleId><ArticleId IdType="pmc">PMC2908374</ArticleId><ArticleId IdType="pubmed">20222805</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney RK, Murphy J, Forshew D, Garwood E, Miller BL, Langmore S, et al.. The effects of executive and behavioral dysfunction on the course of ALS. Neurology. 2005;65:1774&#x2013;1777. doi: 10.1212/01.wnl.0000188759.87240.8b</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000188759.87240.8b</ArticleId><ArticleId IdType="pubmed">16344521</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley SC, Strong MJ. Frontotemporal Dysfunction and Dementia in Amyotrophic Lateral Sclerosis. Neurol Clin, 2015. 33(4): p. 787&#x2013;805 doi: 10.1016/j.ncl.2015.07.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.011</ArticleId><ArticleId IdType="pubmed">26515622</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeldman E, Govaarts R, de Visser M, Klein Twennaar M, van der Kooi AJ, van den Berg LH, et al.. Progression of cognitive and behavioural impairment in early amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2020; 91(7):779&#x2013;780. doi: 10.1136/jnnp-2020-322992</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322992</ArticleId><ArticleId IdType="pmc">PMC7361007</ArticleId><ArticleId IdType="pubmed">32404381</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>